Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
173
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,075.40 | 9.50 | 0.10% |
| CAC 40 | 8,273.84 | 11.68 | 0.14% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 55,699.53 | 1,445.85 | 2.66% |
| NZX 50 Index | 13,398.23 | 45.79 | -0.34% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,817.20 | 6.30 | 0.07% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |